These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30019101)

  • 61. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
    Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
    BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Zhao Y; Li H; Bai W; Liu J; Lv W; Sahu S; Guan S; Qin X; Wang W; Ren W; Mu W; Guo W; Gu S; Ma Y; Yin Z; Guo W; Wang W; Wang Y; Duran R; Fan D; Zhang Z; Han G
    Int J Cancer; 2016 Aug; 139(4):928-37. PubMed ID: 27038145
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
    Marasco G; Colecchia A; Bacchi Reggiani ML; Celsa C; Farinati F; Giannini EG; Benevento F; Rapaccini GL; Caturelli E; Di Marco M; Biasini E; Marra F; Morisco F; Foschi FG; Zoli M; Gasbarrini A; Baroni GS; Masotto A; Sacco R; Raimondo G; Azzaroli F; Mega A; Vidili G; Brunetto MR; Nardone G; Dajti E; Ravaioli F; Avanzato F; Festi D; Trevisani F;
    Dig Liver Dis; 2021 Aug; 53(8):1011-1019. PubMed ID: 33353858
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
    Branco F; Alencar RS; Volt F; Sartori G; Dode A; Kikuchi L; Tani CM; Chagas AL; Pfiffer T; Hoff P; Carrilho FJ; Mattos AA
    Ann Hepatol; 2017; 16(2):263-268. PubMed ID: 28233750
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T; Zhang W; Wu Q; Kong D; Ma W
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
    Díaz-González Á; Sapena V; Boix L; Torres F; Sanduzzi-Zamparelli M; Da Fonseca LG; LLarch N; Iserte G; Guedes C; Muñoz-Martínez S; Darnell A; Belmonte E; Rimola J; Forner A; Ayuso C; Bruix J; Reig M
    United European Gastroenterol J; 2021 Jul; 9(6):655-661. PubMed ID: 34228394
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
    Kim H; Yu SJ; Yeo I; Cho YY; Lee DH; Cho Y; Cho EJ; Lee JH; Kim YJ; Lee S; Jun J; Park T; Yoon JH; Kim Y
    Mol Cell Proteomics; 2017 Jul; 16(7):1312-1323. PubMed ID: 28550167
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
    Zhao P; Chen D; Chen W; Yin XY; Yang D; Liang LJ
    Zhonghua Wai Ke Za Zhi; 2012 Jun; 50(6):514-7. PubMed ID: 22943944
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
    Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
    J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.
    Abuhelwa AY; Badaoui S; Yuen HY; McKinnon RA; Ruanglertboon W; Shankaran K; Tuteja A; Sorich MJ; Hopkins AM
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):479-485. PubMed ID: 35226112
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
    Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Elsayed ZA
    Dig Dis Sci; 2013 Dec; 58(12):3389-96. PubMed ID: 24046163
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
    Qu XD; Chen CS; Wang JH; Yan ZP; Chen JM; Gong GQ; Liu QX; Luo JJ; Liu LX; Liu R; Qian S
    BMC Cancer; 2012 Jun; 12():263. PubMed ID: 22721173
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
    Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Wu Q; Zhang T; Kong D; Li Q; Song T
    Med Oncol; 2015 Apr; 32(4):107. PubMed ID: 25750040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.